Litcius/Paper detail

Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis

Thierry Landré, G. Des Guetz, Kader Chouahnia, Virginie Fossey-Diaz, Stéphane Culine

2020Drugs & Aging38 citationsDOI

Topics & Concepts

MedicineAtezolizumabPembrolizumabNivolumabIpilimumabInternal medicineAvelumabHazard ratioLung cancerOncologyCancerConfidence intervalImmunotherapyCancer Immunotherapy and BiomarkersMultiple and Secondary Primary CancersInflammatory Biomarkers in Disease Prognosis
Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis | Litcius